Curatio DL
Curatio DL24
About
What does Curatio DL do?
Curatio DL provides advanced cancer management solutions by leveraging deep learning-powered pathology analysis. Their technology delivers accurate diagnosis and prognosis, enabling personalized treatment plans for cancer patients.
What is Curatio DL's revenue?
StartupHub estimates Curatio DL's annual revenue at $349K (range $222K to $881K, 65% confidence), based on comparable companies in the sector.
Where is Curatio DL headquartered?
Curatio DL is headquartered in Tel Aviv, Israel.
When was Curatio DL founded?
Curatio DL was founded in 2017.
What industry does Curatio DL operate in?
Curatio DL operates in Healthcare, Pathology, Cancer, HealthTech, MedTech, AI-Driven Drug Discovery.
How many employees does Curatio DL have?
Curatio DL has approximately 2 people on record.
What is Curatio DL's current status?
Curatio DL's current operating status is: Inactive.
Lymesignal is an AI-assisted platform that transforms publicly available Lyme disease discussions into organized, searchable community knowledge.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
A science-based digital program and app designed to help adults manage ADHD symptoms and build coping skills.
AI-powered platform for personalized weight management and health coaching.
Recordatorios por WhatsApp para el paciente y tranquilidad para quien lo acompaƱa. Gratis, sin apps que descargar.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 11 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.